Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of AI-081 in advanced solid tumors
CTR20253261Phase 2Active
- Sponsor
- OncoC4
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cesalatamig in Nonhematologic neoplasms, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), ovarian cancer, sponsored by OncoC4. Started Sep 2025; status: active.
02
Drugs
cesalatamig
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)ovarian cancer
Beyond the preview
Go deeper on CTR20253261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253261.